Biomarkers Consortium Launches Adaptive Trial To Test Targeted Breast Cancer Drugs
The five-year I-SPY 2 study is a model for drug development and an innovative screening process for identifying winners, FDA's Woodcock says.
The five-year I-SPY 2 study is a model for drug development and an innovative screening process for identifying winners, FDA's Woodcock says.